Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 11/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752579 | 0.81 | CYP2C19 (0.44) | MAPTLMNACYP2C19 | |
| SCHEMBL30032785 | 0.81 | CYP2C19 (0.44) | MAPTLMNACYP2C19 | |
| SCHEMBL25975832 | 0.79 | PDCD1 (0.42) | PDCD1CD274MAPTLMNACYP2C19 | |
| SCHEMBL31362508 | 0.78 | DRD2 (0.44) | DRD2 | |
| SCHEMBL25429414 | 0.70 | MAPK1 (0.49) | MAPT | |
| SCHEMBL21622307 | 0.70 | JAK2 (0.34) | PDCD1CD274LMNACYP2C19 | |
| SCHEMBL21937114 | 0.70 | ABHD6 (0.42) | MAPTCYP2C19CYP2D6TP53 | |
| SCHEMBL2693254 | 0.70 | ADRA2A (0.47) | — | |
| SCHEMBL20038584 | 0.70 | PDCD1 (0.45) | PDCD1CD274DRD2MAPTLMNA | |
| SCHEMBL31362571 | 0.69 | DRD2 (0.46) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |